IFN-γ-loaded nanoparticles can be administered either intratumorally or systemically to aid in tumor rejection by enhancing CD4+ T-cell function and facilitating CTL priming (Schroder et al., 2004). The gene discussed is IFNG; the disease is neoplasm.